Overview
Osteoarthritis of the knee is the most frequently studied indication for Boswellia serrata extracts. It represents the most studied application in the published literature, with multiple randomized controlled trials (RCTs) and at least one meta-analysis reporting statistically significant differences in pain and function measures compared to placebo. However, several important caveats apply: most trials are small, the majority were conducted or funded by the patent holders of proprietary extracts, and independent replication remains limited.
This page summarizes the current research landscape, including what the evidence shows, where it falls short, and what is not yet known.
This summary covers clinical trials in humans only. Laboratory (in vitro) and animal studies involving inflammatory pathways associated with joint tissue are discussed on the Inflammation & Inflammatory Pathways page. Mechanistic findings in laboratory settings do not establish clinical efficacy. Dosage ranges used in trials are summarized on the Dosage Guide page.
What the Research Has Examined
Clinical trials have primarily evaluated standardized Boswellia serrata extracts — most commonly AKBA-enriched formulations (such as Aflapin® and 5-Loxin®) and standard 65% boswellic acid extracts — in adults with mild-to-moderate knee osteoarthritis (OA). Outcome measures across trials have included:
- Self-reported pain scores (visual analogue scale, WOMAC pain subscale)
- Physical function measures (WOMAC function subscale, 6-minute walk test)
- Joint stiffness scores
- Inflammatory biomarkers (CRP, MMP-3 in some trials)
- Rescue medication use
Most trials enrolled participants over 8–12 weeks. Longer-duration trials (beyond 6 months) are scarce, limiting conclusions about sustained effects or safety over extended use.
Key Published Trials
| Study | Design | Extract / Dose | Duration | Key Finding | Funding |
|---|---|---|---|---|---|
| Sengupta et al. (2010) PubMed ↗ |
RCT, double-blind, placebo-controlled; n=60 | Aflapin® 100 mg/day | 90 days | Statistically significant differences in WOMAC pain and function scores vs. placebo. Effect sizes not independently validated. | Industry (Sabinsa Corp.) |
| Vishal et al. (2011) PubMed ↗ |
RCT, double-blind, placebo-controlled; n=60 | Aflapin® vs. 5-Loxin® vs. placebo | 90 days | Both extracts showed statistically significant improvements in VAS pain and WOMAC scores. Aflapin® appeared to act faster (30 days vs. 60 days for 5-Loxin®). Industry-funded; requires independent replication. | Industry (Sabinsa Corp.) |
| Kizhakkedath (2013) PubMed ↗ |
RCT, double-blind; n=72 | Boswellia + curcumin combination vs. celecoxib | 12 weeks | Combination reported non-inferior outcomes to celecoxib on pain and function measures. Combination makes it difficult to isolate Boswellia's contribution. | Industry |
| Majeed et al. (2019) PubMed ↗ |
RCT, double-blind, placebo-controlled; n=104 | Boswellia 500 mg/day (65% boswellic acids) | 90 days | Significant reductions in VAS pain scores and improvements in functional capacity. Larger sample size than earlier trials but still industry-affiliated. | Industry (Sami Labs) |
| Yu et al. (2020) — Meta-analysis PubMed ↗ |
Systematic review and meta-analysis; 7 RCTs, n=545 | Various Boswellia extracts | Varied (4–24 weeks) | Statistically significant pooled differences in pain (SMD −0.74) and function (SMD −0.69) vs. placebo. Authors noted risk of bias from industry funding and small sample sizes. Clinical significance of effect sizes uncertain. | Academic (China); underlying trials largely industry-funded |
Findings summarized above reflect outcomes within specific study populations under controlled conditions. Results from individual trials do not establish equivalence to standard medical care and may not generalize to broader patient populations. Independent replication and longer-duration studies are often limited.
- Multiple RCTs have reported statistically significant differences in pain and function scores vs. placebo over 8–12 weeks
- A 2020 meta-analysis (n=545) found pooled significant effects on both pain and physical function outcomes
- Both high-AKBA enriched extracts and standard extracts have been evaluated in trials
- Onset of reported effects in some trials was observed from 30–60 days
- Tolerability in trials was generally reported as good, with GI discomfort as the most common adverse event
- Clinical significance of observed effect sizes — SMDs of ~0.7 are statistically significant but their real-world meaningfulness is debated
- Whether effects persist beyond 12 weeks — long-term trial data are limited
- Whether findings from industry-funded trials would replicate in independently funded research
- Optimal dose and extract type — trials have used varying formulations, making direct comparisons difficult
- Effects in populations beyond mild-to-moderate knee OA (e.g., hip OA, severe OA, RA)
- Whether Boswellia extracts modify disease progression or only affect symptom scores
Research Limitations
The current evidence base for Boswellia serrata in joint health is subject to several important limitations that affect confidence in the findings:
Industry funding concentration
The majority of published RCTs in this area were funded by or conducted in affiliation with the companies holding patents on proprietary Boswellia extracts (primarily Sabinsa Corporation and Sami Labs). This introduces potential bias in study design, outcome selection, and reporting. Independent replication by non-affiliated research groups remains limited.
Small sample sizes
Most individual trials enrolled between 30 and 100 participants. Small samples increase the risk of chance findings and reduce statistical power to detect modest effects reliably. The largest trial identified in this review enrolled 104 participants.
Short trial durations
The majority of trials ran for 8–12 weeks. Osteoarthritis is a chronic condition; trials of this length cannot address the question of long-term efficacy, safety, or disease modification.
Heterogeneity of extracts
Trials have used different extract types (standard boswellic acid extracts, AKBA-enriched formulations, combination products), different doses, and different outcome instruments, making cross-trial comparisons difficult and pooled analyses harder to interpret.
Risk of bias in meta-analyses
The 2020 Yu et al. meta-analysis — the most comprehensive available — explicitly noted high risk of bias from industry funding and small trial sizes, and rated overall evidence quality as moderate to low. The pooled effect sizes should be interpreted with these caveats in mind.
Safety Considerations
GI Discomfort
The most commonly reported adverse effect in trials. Typically described as mild and transient. Taking with food may reduce occurrence.
Long-term Safety
Controlled safety data beyond 12 weeks are limited. Use beyond this period has not been adequately studied in clinical trials.
Drug Interactions
In laboratory studies, boswellic acids have been shown to interact with drug transporter proteins (OATP1B3, MRP2). Clinical significance is not fully established. Discuss with a pharmacist if taking prescription medications, particularly those with narrow therapeutic windows.
Pregnancy & Breastfeeding
Safety has not been established in pregnancy or breastfeeding. Avoid use without explicit guidance from a healthcare provider.
This information does not constitute medical advice. Consult your physician or pharmacist before starting any supplement regimen, particularly if you have a diagnosed medical condition, are taking prescription medications, or are awaiting surgery.
References
- 1Sengupta K, et al. (2010). A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Research & Therapy. PubMed ↗
- 2Vishal AA, et al. (2011). A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee. International Journal of Medical Sciences. PubMed ↗
- 3Kizhakkedath R. (2013). Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis. Molecular Medicine Reports. PubMed ↗
- 4Majeed M, et al. (2019). A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytotherapy Research. PubMed ↗
- 5Yu G, et al. (2020). Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. PubMed ↗
- 6Bannuru RR, et al. (2015). Comparative effectiveness of pharmacological interventions for knee osteoarthritis. Annals of Internal Medicine. PubMed ↗
Regulatory Context
Boswellia serrata extracts are regulated in the United States as dietary supplements, not as drugs. They are not approved by the U.S. Food and Drug Administration for the treatment, prevention, or cure of any disease. Clinical research findings summarized on this page do not constitute regulatory approval or medical guidance.